Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

PP4-dependent HDAC3 dephosphorylation discriminates between axonal regeneration and regenerative failure.

Hervera A, Zhou L, Palmisano I, McLachlan E, Kong G, Hutson TH, Danzi MC, Lemmon VP, Bixby JL, Matamoros-Angles A, Forsberg K, De Virgiliis F, Matheos DP, Kwapis J, Wood MA, Puttagunta R, Del Río JA, Di Giovanni S.

EMBO J. 2019 Jul 1;38(13):e101032. doi: 10.15252/embj.2018101032. Epub 2019 May 22.

PMID:
31268609
2.

PP4-dependent HDAC3 dephosphorylation discriminates between axonal regeneration and regenerative failure.

Hervera A, Zhou L, Palmisano I, McLachlan E, Kong G, Hutson TH, Danzi MC, Lemmon VP, Bixby JL, Matamoros-Angles A, Forsberg K, De Virgiliis F, Matheos DP, Kwapis J, Wood MA, Puttagunta R, Del Río JA, Di Giovanni S.

EMBO J. 2019 May 22. pii: e101032. doi: 10.15252/embj.2018101032. [Epub ahead of print]

PMID:
31118250
3.

Cbp-dependent histone acetylation mediates axon regeneration induced by environmental enrichment in rodent spinal cord injury models.

Hutson TH, Kathe C, Palmisano I, Bartholdi K, Hervera A, De Virgiliis F, McLachlan E, Zhou L, Kong G, Barraud Q, Danzi MC, Medrano-Fernandez A, Lopez-Atalaya JP, Boutillier AL, Sinha SH, Singh AK, Chaturbedy P, Moon LDF, Kundu TK, Bixby JL, Lemmon VP, Barco A, Courtine G, Di Giovanni S.

Sci Transl Med. 2019 Apr 10;11(487). pii: eaaw2064. doi: 10.1126/scitranslmed.aaw2064.

4.

Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.

Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ.

Future Oncol. 2019 Mar;15(9):929-941. doi: 10.2217/fon-2018-0745. Epub 2019 Jan 28.

5.

Connectivity and Centrality Characteristics of the Epileptogenic Focus Using Directed Network Analysis.

Adkinson JA, Karumuri B, Hutson TN, Liu R, Alamoudi O, Vlachos I, Iasemidis L.

IEEE Trans Neural Syst Rehabil Eng. 2019 Jan;27(1):22-30. doi: 10.1109/TNSRE.2018.2886211. Epub 2018 Dec 11.

PMID:
30561346
6.

Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.

Basch EM, Scholz M, de Bono JS, Vogelzang N, de Souza P, Marx G, Vaishampayan U, George S, Schwarz JK, Antonarakis ES, O'Sullivan JM, Kalebasty AR, Chi KN, Dreicer R, Hutson TE, Dueck AC, Bennett AV, Dayan E, Mangeshkar M, Holland J, Weitzman AL, Scher HI.

Eur Urol. 2019 Jun;75(6):929-937. doi: 10.1016/j.eururo.2018.11.033. Epub 2018 Dec 4.

7.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z.

PMID:
30291359
8.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Erratum in: Nat Med. 2018 Dec;24(12):1941.

PMID:
29867230
9.

Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.

Rini BI, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, Rosbrook B, Motzer RJ.

Clin Genitourin Cancer. 2018 Aug;16(4):298-304. doi: 10.1016/j.clgc.2018.04.005. Epub 2018 May 4.

10.

Predictability and Resetting in a Case of Convulsive Status Epilepticus.

Hutson T, Pizarro D, Pati S, Iasemidis LD.

Front Neurol. 2018 Mar 22;9:172. doi: 10.3389/fneur.2018.00172. eCollection 2018.

11.

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.

Molina AM, Hutson TE, Nosov D, Tomczak P, Lipatov O, Sternberg CN, Motzer R, Eisen T.

Eur J Cancer. 2018 May;94:87-94. doi: 10.1016/j.ejca.2018.02.009. Epub 2018 Mar 20.

12.

Publisher Correction: Reactive oxygen species regulate axonal regeneration through the release of exosomal NADPH oxidase 2 complexes into injured axons.

Hervera A, De Virgiliis F, Palmisano I, Zhou L, Tantardini E, Kong G, Hutson T, Danzi MC, Perry RB, Santos CXC, Kapustin AN, Fleck RA, Del Río JA, Carroll T, Lemmon V, Bixby JL, Shah AM, Fainzilber M, Di Giovanni S.

Nat Cell Biol. 2018 Sep;20(9):1098. doi: 10.1038/s41556-018-0063-x.

PMID:
29520084
13.

Reactive oxygen species regulate axonal regeneration through the release of exosomal NADPH oxidase 2 complexes into injured axons.

Hervera A, De Virgiliis F, Palmisano I, Zhou L, Tantardini E, Kong G, Hutson T, Danzi MC, Perry RB, Santos CXC, Kapustin AN, Fleck RA, Del Río JA, Carroll T, Lemmon V, Bixby JL, Shah AM, Fainzilber M, Di Giovanni S.

Nat Cell Biol. 2018 Mar;20(3):307-319. doi: 10.1038/s41556-018-0039-x. Epub 2018 Feb 12. Erratum in: Nat Cell Biol. 2018 Mar 8;:.

PMID:
29434374
14.

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK.

J Clin Oncol. 2018 Mar 10;36(8):757-764. doi: 10.1200/JCO.2017.75.2170. Epub 2018 Jan 29.

PMID:
29377755
15.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, Rha SY, Vaishampayan U, Harris WB, Richey S, Randall JM, Shaffer D, Cohn A, Crowell T, Li J, Senderowicz A, Stone E, Figlin R, Motzer RJ, Haas NB, Hutson T.

Ann Oncol. 2017 Nov 1;28(11):2754-2760. doi: 10.1093/annonc/mdx493.

PMID:
28950297
16.

New treatment options for metastatic renal cell carcinoma.

Rodriguez-Vida A, Hutson TE, Bellmunt J, Strijbos MH.

ESMO Open. 2017 May 9;2(2):e000185. doi: 10.1136/esmoopen-2017-000185. eCollection 2017. Review.

17.

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma.

Zurita AJ, Gagnon RC, Liu Y, Tran HT, Figlin RA, Hutson TE, D'Amelio AM Jr, Sternberg CN, Pandite LN, Heymach JV.

Br J Cancer. 2017 Aug 8;117(4):478-484. doi: 10.1038/bjc.2017.206. Epub 2017 Jul 6.

18.

Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers.

Hutson TE, Jiao X, Wilson T, Cisar L, MacLean EA.

Future Oncol. 2017 Jun;13(15):1323-1332. doi: 10.2217/fon-2016-0566. Epub 2017 May 9.

PMID:
28485672
19.

Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma.

Rini BI, Gruenwald V, Jonasch E, Fishman MN, Tomita Y, Michaelson MD, Tarazi J, Cisar L, Hariharan S, Bair AH, Rosbrook B, Hutson TE.

Target Oncol. 2017 Jun;12(3):333-340. doi: 10.1007/s11523-017-0487-4.

PMID:
28361451
20.

Scn2a deletion improves survival and brain-heart dynamics in the Kcna1-null mouse model of sudden unexpected death in epilepsy (SUDEP).

Mishra V, Karumuri BK, Gautier NM, Liu R, Hutson TN, Vanhoof-Villalba SL, Vlachos I, Iasemidis L, Glasscock E.

Hum Mol Genet. 2017 Jun 1;26(11):2091-2103. doi: 10.1093/hmg/ddx104.

21.

Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial.

Motzer RJ, Figlin RA, Martini JF, Hariharan S, Agarwal N, Li CX, Williams JA, Hutson TE.

Clin Genitourin Cancer. 2017 Oct;15(5):526-533. doi: 10.1016/j.clgc.2017.02.006. Epub 2017 Feb 27.

PMID:
28330808
22.

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.

Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB.

J Immunother Cancer. 2016 Nov 15;4:81. eCollection 2016.

23.

Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma.

Rodriguez-Vida A, Strijbos M, Hutson T.

ESMO Open. 2016 May 25;1(3):e000013. eCollection 2016. Review.

24.
25.

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.

Vogelzang NJ, Fizazi K, Burke JM, De Wit R, Bellmunt J, Hutson TE, Crane E, Berry WR, Doner K, Hainsworth JD, Wiechno PJ, Liu K, Waldman MF, Gandhi A, Barton D, Jungnelius U, Fandi A, Sternberg CN, Petrylak DP.

Eur Urol. 2017 Feb;71(2):168-171. doi: 10.1016/j.eururo.2016.07.051. Epub 2016 Aug 10.

PMID:
27522164
26.

Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.

Hutson TE, Al-Shukri S, Stus VP, Lipatov ON, Shparyk Y, Bair AH, Rosbrook B, Andrews GI, Vogelzang NJ.

Clin Genitourin Cancer. 2017 Feb;15(1):72-76. doi: 10.1016/j.clgc.2016.05.008. Epub 2016 May 27.

PMID:
27498023
27.

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.

Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bögemann M, Hutson T, Milecki P, Chowdhury S, Gallardo E, Schwartsmann G, Pouget JC, Baton F, Nederman T, Tuvesson H, Carducci M.

J Clin Oncol. 2016 Aug 1;34(22):2636-43. doi: 10.1200/JCO.2016.66.9697. Epub 2016 Jun 13.

28.

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.

Bono P, Oudard S, Bodrogi I, Hutson TE, Escudier B, Machiels JP, Thompson JA, Figlin RA, Ravaud A, Basaran M, Porta C, Bracarda S, Brechenmacher T, Lin C, Voi M, Grunwald V, Motzer RJ.

Clin Genitourin Cancer. 2016 Oct;14(5):406-414. doi: 10.1016/j.clgc.2016.04.011. Epub 2016 Apr 27.

29.

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.

Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators.

Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5.

PMID:
27279544
30.

The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma.

Hutson TE, Thoreson GR, Figlin RA, Rini BI.

Am Soc Clin Oncol Educ Book. 2016;35:113-7. doi: 10.14694/EDBK_158892. Review.

31.

The Adaptor Protein CD2AP Is a Coordinator of Neurotrophin Signaling-Mediated Axon Arbor Plasticity.

Harrison BJ, Venkat G, Lamb JL, Hutson TH, Drury C, Rau KK, Bunge MB, Mendell LM, Gage FH, Johnson RD, Hill CE, Rouchka EC, Moon LD, Petruska JC.

J Neurosci. 2016 Apr 13;36(15):4259-75. doi: 10.1523/JNEUROSCI.2423-15.2016.

32.

Overexpression of the Fibroblast Growth Factor Receptor 1 (FGFR1) in a Model of Spinal Cord Injury in Rats.

Haenzi B, Gers-Barlag K, Akhoundzadeh H, Hutson TH, Menezes SC, Bunge MB, Moon LD.

PLoS One. 2016 Mar 25;11(3):e0150541. doi: 10.1371/journal.pone.0150541. eCollection 2016.

33.

Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.

Motzer RJ, Hutson TE, Ren M, Dutcus C, Larkin J.

Lancet Oncol. 2016 Jan;17(1):e4-5. doi: 10.1016/S1470-2045(15)00543-4. Epub 2015 Dec 23. No abstract available.

PMID:
26758760
34.

Sequential Therapy in Metastatic Renal Cell Carcinoma.

Hirsch BR, Burke JM, Agrawal M, Hauke RJ, Hutson TE, Doshi G, Fleming MT, Vogelzang NJ.

J Kidney Cancer VHL. 2016 Apr 5;3(1):23-35. doi: 10.15586/jkcvhl.2016.46. eCollection 2016. Review.

35.

Transcriptional changes in sensory ganglia associated with primary afferent axon collateral sprouting in spared dermatome model.

Harrison BJ, Venkat G, Hutson T, Rau KK, Bunge MB, Mendell LM, Gage FH, Johnson RD, Hill C, Rouchka EC, Moon L, Petruska JC.

Genom Data. 2015 Oct 23;6:249-52. doi: 10.1016/j.gdata.2015.10.005. eCollection 2015 Dec.

36.

Trans-neuronal transduction of spinal neurons following cortical injection and anterograde axonal transport of a bicistronic AAV1 vector.

Hutson TH, Kathe C, Moon LD.

Gene Ther. 2016 Feb;23(2):231-6. doi: 10.1038/gt.2015.103. Epub 2015 Dec 10.

37.

Delayed intramuscular human neurotrophin-3 improves recovery in adult and elderly rats after stroke.

Duricki DA, Hutson TH, Kathe C, Soleman S, Gonzalez-Carter D, Petruska JC, Shine HD, Chen Q, Wood TC, Bernanos M, Cash D, Williams SC, Gage FH, Moon LD.

Brain. 2016 Jan;139(Pt 1):259-75. doi: 10.1093/brain/awv341. Epub 2015 Nov 27.

38.

Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions.

Porta C, Tortora G, Larkin JM, Hutson TE.

Future Oncol. 2016 Feb;12(4):533-49. doi: 10.2217/fon.15.313. Epub 2015 Nov 26. Review.

39.

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J.

Lancet Oncol. 2015 Nov;16(15):1473-1482. doi: 10.1016/S1470-2045(15)00290-9. Epub 2015 Oct 22. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270. Lancet Oncol. 2018 Oct;19(10):e509.

PMID:
26482279
40.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators.

N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.

41.

Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.

Powles T, Bracarda S, Chen M, Norry E, Compton N, Heise M, Hutson T, Harter P, Carpenter C, Pandite L, Kaplowitz N.

Eur J Cancer. 2015 Jul;51(10):1293-302. doi: 10.1016/j.ejca.2015.03.019. Epub 2015 Apr 17. Review.

PMID:
25899987
42.

A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma.

Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopoulos J, Kanesvaran R, Lauer R, Starodub A, Hauke R, Sweeney CJ, Hahn NM, Sonpavde G, Richey S, Breen T, Kremmidiotis G, Leske A, Doolin E, Bibby DC, Simpson J, Iglesias J, Hutson T.

Clin Cancer Res. 2015 Aug 1;21(15):3420-7. doi: 10.1158/1078-0432.CCR-14-3370. Epub 2015 Mar 18.

43.

Unilateral pyramidotomy of the corticospinal tract in rats for assessment of neuroplasticity-inducing therapies.

Kathe C, Hutson TH, Chen Q, Shine HD, McMahon SB, Moon LD.

J Vis Exp. 2014 Dec 15;(94). doi: 10.3791/51843.

44.

First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.

Vogelzang NJ, Hackshaw MD, Hutson TE, Bhowmik D, Yap M, Rembert D, Jonasch E.

Clin Genitourin Cancer. 2015 Jun;13(3):210-7. doi: 10.1016/j.clgc.2014.11.001. Epub 2014 Nov 15.

PMID:
25498215
45.

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.

Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L.

Br J Cancer. 2014 Nov 11;111(10):1909-16. doi: 10.1038/bjc.2014.503. Epub 2014 Oct 28. Erratum in: Br J Cancer. 2014 Dec 9;111(12):2383.

46.

Dosing patterns, toxicity, and outcomes in patients treated with first-line sunitinib for advanced renal cell carcinoma in community-based practices.

Schnadig ID, Hutson TE, Chung H, Dhanda R, Halm M, Forsyth M, Vogelzang NJ.

Clin Genitourin Cancer. 2014 Dec;12(6):413-21. doi: 10.1016/j.clgc.2014.06.015. Epub 2014 Jun 21.

PMID:
25163396
47.

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.

Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, Huang X, Valota O, Williams JA.

Cancer Chemother Pharmacol. 2014 Oct;74(4):739-50. doi: 10.1007/s00280-014-2539-0. Epub 2014 Aug 7.

48.

Practice challenges affecting optimal care as identifed by US medical oncologists who treat renal cell carcinomas.

Hayes SM, Bowser AD, Mortimer J, Lazure P, Peterson E, Hutson TE, Rini B.

J Community Support Oncol. 2014 Jun;12(6):197-204.

PMID:
24999496
49.

The use of an adeno-associated viral vector for efficient bicistronic expression of two genes in the central nervous system.

Hutson TH, Kathe C, Menezes SC, Rooney MC, Bueler H, Moon LD.

Methods Mol Biol. 2014;1162:189-207. doi: 10.1007/978-1-4939-0777-9_16.

50.

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.

Escudier B, Michaelson MD, Motzer RJ, Hutson TE, Clark JI, Lim HY, Porfiri E, Zalewski P, Kannourakis G, Staehler M, Tarazi J, Rosbrook B, Cisar L, Hariharan S, Kim S, Rini BI.

Br J Cancer. 2014 Jun 10;110(12):2821-8. doi: 10.1038/bjc.2014.244. Epub 2014 May 13.

Supplemental Content

Loading ...
Support Center